BACKGROUND: In recent years, laparoscopic sleeve gastrectomy (LSG) has become one of the most commonly used primary bariatric procedures for morbid obesity. While laparoscopic Roux-en-Y gastric bypass (LRYGB) has well documented positive clinical influence on type 2 diabetes, the role of LSG in diabetes treatment is debatable. The main aim of this study is to present our early experience in LSG as a method of bariatric treatment in patients with type 2 diabetes or abnormalities in glucose homeostasis. METHODS: Prospectively collected data of patients operated for morbid obesity at the 2nd Department of Surgery. The study was designed to assess the influence of LSG on type 2 diabetes and glucose homeostasis. The primary endpoint was the diabetes type 2 remission. Secondary endpoint was the change of glucose metabolism parameters after LSG. Patients were assessed preoperatively and allocated to two groups: group 1-with any preoperative abnormalities in glucose homeostasis (prediabetes, diabetes) and group 2-with non-elevated fasting glucose level. During follow-up (6 months after surgery) all glucose homeostasis parameters were analyzed again. One hundred and thirty-six patients after LSG were enrolled in the study (90 females, 46 males; mean age 40.5±9.9 years). Preoperative abnormalities in glucose homeostasis were confirmed in 64 (47%) patients. Twenty (15%) patients in this group had diabetes. RESULTS: We observed significant reduction of body mass index (BMI) after surgery. Mean percent of EBMIL for all groups after 6 months from surgery was 59.90% (46.75-69.28%). There were no full remissions after surgery in patients with preoperative diabetes. We found significant improvement in biochemical markers of glucose homeostasis. We observed significant reduction of HbA1c% after surgery in both groups. The level of postoperative HbA1c% was related to BMI loss after surgery. CONCLUSIONS: LSG leads to significant improvement in biochemical glucose homeostasis and can be considered as a method of treatment in morbidly obese patients with glucose metabolism abnormalities. LSG as a method of treatment for patients with clinical type 2 diabetes still needs some further observation.
BACKGROUND: In recent years, laparoscopic sleeve gastrectomy (LSG) has become one of the most commonly used primary bariatric procedures for morbid obesity. While laparoscopic Roux-en-Y gastric bypass (LRYGB) has well documented positive clinical influence on type 2 diabetes, the role of LSG in diabetes treatment is debatable. The main aim of this study is to present our early experience in LSG as a method of bariatric treatment in patients with type 2 diabetes or abnormalities in glucose homeostasis. METHODS: Prospectively collected data of patients operated for morbid obesity at the 2nd Department of Surgery. The study was designed to assess the influence of LSG on type 2 diabetes and glucose homeostasis. The primary endpoint was the diabetes type 2 remission. Secondary endpoint was the change of glucose metabolism parameters after LSG. Patients were assessed preoperatively and allocated to two groups: group 1-with any preoperative abnormalities in glucose homeostasis (prediabetes, diabetes) and group 2-with non-elevated fasting glucose level. During follow-up (6 months after surgery) all glucose homeostasis parameters were analyzed again. One hundred and thirty-six patients after LSG were enrolled in the study (90 females, 46 males; mean age 40.5±9.9 years). Preoperative abnormalities in glucose homeostasis were confirmed in 64 (47%) patients. Twenty (15%) patients in this group had diabetes. RESULTS: We observed significant reduction of body mass index (BMI) after surgery. Mean percent of EBMIL for all groups after 6 months from surgery was 59.90% (46.75-69.28%). There were no full remissions after surgery in patients with preoperative diabetes. We found significant improvement in biochemical markers of glucose homeostasis. We observed significant reduction of HbA1c% after surgery in both groups. The level of postoperative HbA1c% was related to BMI loss after surgery. CONCLUSIONS: LSG leads to significant improvement in biochemical glucose homeostasis and can be considered as a method of treatment in morbidly obesepatients with glucose metabolism abnormalities. LSG as a method of treatment for patients with clinical type 2 diabetes still needs some further observation.
Authors: Ali Aminian; Stacy A Brethauer; Amin Andalib; Suriya Punchai; Jennifer Mackey; John Rodriguez; Tomasz Rogula; Matthew Kroh; Philip R Schauer Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Marco Milone; Matteo Nicola Dario Di Minno; Maddalena Leongito; Paola Maietta; Paolo Bianco; Caterina Taffuri; Dario Gaudioso; Roberta Lupoli; Silvia Savastano; Francesco Milone; Mario Musella Journal: World J Gastroenterol Date: 2013-10-21 Impact factor: 5.742
Authors: Darline Garibay; Anne K McGavigan; Seon A Lee; James V Ficorilli; Amy L Cox; M Dodson Michael; Kyle W Sloop; Bethany P Cummings Journal: Endocrinology Date: 2016-08-08 Impact factor: 4.736
Authors: Piotr Major; Maciej Matłok; Michał Pędziwiatr; Marcin Migaczewski; Piotr Budzyński; Maciej Stanek; Michał Kisielewski; Michał Natkaniec; Andrzej Budzyński Journal: Obes Surg Date: 2015-09 Impact factor: 4.129
Authors: Piotr Major; Maciej Matłok; Michał Pędziwiatr; Marcin Migaczewski; Anna Zub-Pokrowiecka; Dorota Radkowiak; Marek Winiarski; Anna Zychowicz; Danuta Fedak; Andrzej Budzyński Journal: Wideochir Inne Tech Maloinwazyjne Date: 2015-09-11 Impact factor: 1.195